Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: A pilot study

Photodiagnosis and Photodynamic Therapy

Volumn 8, Issue 1, 2011, Pages 1-6

  Cassidy, Corona M ^a   Tunney, Michael M ^a   Magee, Nicholas D ^b   Elborn, J Stuart ^b   Bell, Steven ^a   Singh, Thakur Raghu Raj ^a   Donnelly, Ryan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Medical Biology Centre   (United Kingdom)

Author keywords

Light delivery; Methylene blue; Pulmonary drug delivery

Indexed keywords

ANTIINFECTIVE AGENT; METHYLENE BLUE;

ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; EX VIVO STUDY; FIBER OPTICS; HELIUM NEON LASER; IN VITRO STUDY; IN VIVO STUDY; LUNG LOBE; LUNG MODEL; LUNG PARENCHYMA; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DRUG COMPOUNDING; LUNG; METHYLENE BLUE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RADIATION TOLERANCE; SCATTERING, RADIATION; SWINE; TISSUE DISTRIBUTION;

BURKHOLDERIA CEPACIA COMPLEX; PSEUDOMONAS AERUGINOSA;

EID: 79951578375     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2010.12.007     Document Type: Article

References (16)

1. McCormick J., Green M.W., Mehta G., Culross F., Mehta A. Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet 2002, 10:583-590.
2. Boucher R.C. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002, 54:1359-1371.
3. Donnelly R.F., McCarron P.A., Tunney M.M. Antifungal photodynamic therapy. Microbiol Res 2008, 163:1-12.
4. Griffiths M.A., Wren B.W., Wilson M. Killing of methicillin-resistant Staphylococcus aureus in vitro using aluminium disulphonated phthalocyanine, a light-activated antimicrobial agent. J Antimicrob Chemother 1997, 40:873-876.
5. Donnelly R.F., McCarron P.A., Cassidy C.M., Elborn J.S., Tunney M.M. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection. J Control Release 2007, 117:217-226.
6. Kuhn K.J. Formulation of aerosolized therapeutics. Chest 2001, 120:94S-98S.
7. Usuda J., Ichinose S., Ishizumi T., et al. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0cm in diameter. Clin Cancer Res 2010, 16:2198-2204.
8. Usuda J., Ichinose S., Ishizumi T., et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J Thorac Oncol 2010, 5:62-68.
9. Tsuda A., Filipovic N., Haberthur D., et al. Finite element 3D reconstruction of the pulmonary acinus imaged by synchrotron X-ray tomography. J Appl Physiol 2008, 105:964-976.
10. Gehr P., Bachofen M., Weibel E.R. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978, 32:121-140.
11. Worlitzsch D., Tarran R., Ulrich M.., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325.
12. Tiddens H.A., Koopman L.P., Lambert R.K., et al. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. Eur Respir J 2000, 15:735-742.
13. Regamey N., Jeffery P.K., Alton E.W., Bush A., Davies J.C. Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax 2010.
14. Laube B.L., Jashnani R., Dalby R.N., Zeitlin P.L. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000, 118:1069-1076.
15. Coates A.L. Guiding aerosol deposition in the lung. N Engl J Med 2008, 358:304-305.
16. Bonam M., Christopher D., Cipolla D., et al. Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech 2008, 9:404-413.